OnKure Therapeutics, Inc.

OnKure Therapeutics (OKUR) reported one material 8-K filing in the past 90 days: an officer departure disclosed on June 4, 2026, alongside related compensation arrangements. No cyber incidents were detected in our monitoring window. While this single event merits context—including whether it signals deeper governance concerns or represents routine turnover—a 90-day snapshot captures limited history. The full $49 Report extends analysis to 12 months of filings, quantifies dilution risk from equity compensation and financing activities, and cross-references officer changes against capital raises and insider trading patterns to assess management stability and shareholder impact.